Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure chronic conditions ...

"ArkBio commences Phase II study of AK0610 for RSV prevention" was originally created and published by Clinical Trials Arena, ...

Study of 2,061 infants reveals RSV, HMPV, influenza, and viral co-infections significantly increase severe lower respiratory ...

EDP-323 significantly reduced mean viral load AUC by 85% and 87% in the high- and low-dose groups, respectively, compared ...

Immunizations used to treat COVID-19, respiratory syncytial virus (RSV) and influenza safely reduce the risk of adverse outcomes among people of all ages, according to a systematic analysis of 511 ...

A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States—sending greater numbers of babies and toddlers to the hospital, recent data show.

Multiple studies have shown that Covid infection increases the risk of cardiovascular diseases, including heart attack and ...

The official spokesman for the Ministry of Health Dr. Abdullah Al-Sanad announced Wednesday that the increase in respiratory ...

HealthTrackRx, a Louisville-based company, is releasing health data while the CDC lags amid an ongoing government shutdown.

First postlicensure season data show high RSV vaccine effectiveness against acute respiratory illness in older adults, ...